ST6GAL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Accordingly, the proportion of ST6GAL1 positive CML/MDR samples was 90.9% (20 of 22), this was found to be significantly higher than the chemosensitive CML group (28.5%, 2 of 7).